Lineage Cell Therapeutics
Stock Forecast, Prediction & Price Target
Lineage Cell Therapeutics Financial Estimates
Lineage Cell Therapeutics Revenue Estimates
Lineage Cell Therapeutics EBITDA Estimates
Lineage Cell Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.89M N/A | $14.70M 277.38% | $8.94M -39.16% | Avg: $5.86M Low: $1.36M High: $10.36M avg. -34.38% | Avg: $22.83M Low: $4.50M High: $52.12M avg. 288.97% | Avg: $34.13M Low: $6.73M High: $77.94M avg. 49.52% | Avg: $65.29M Low: $12.88M High: $149.08M avg. 91.25% |
Net Income
% change YoY
| $-38.56M N/A | $-26.35M 31.66% | $-21.48M 18.46% | Avg: $-32.25M Low: $-43.16M High: $-13.81M avg. -50.10% | Avg: $-30.05M Low: $-50.07M High: $6.90M avg. 6.80% | Avg: $21.58M Low: $-939.08K High: $57.59M avg. 171.81% | Avg: $68.20M Low: $-2.96M High: $181.99M avg. 216% |
EBITDA
% change YoY
| $-52.79M N/A | $-19.82M 62.44% | $-24.04M -21.27% | Avg: $-5.86M Low: $-10.36M High: $-1.36M avg. 75.58% | Avg: $-22.83M Low: $-52.12M High: $-4.50M avg. -288.97% | Avg: $-34.13M Low: $-77.94M High: $-6.73M avg. -49.52% | Avg: $-65.29M Low: $-149.08M High: $-12.88M avg. -91.25% |
EPS
% change YoY
| -$0.23 N/A | -$0.16 30.43% | -$0.12 25.00% | Avg: -$0.17 Low: -$0.25 High: -$0.08 avg. -43.33% | Avg: -$0.15 Low: -$0.29 High: $0.04 avg. 15.69% | Avg: $0.13 Low: -$0.01 High: $0.33 avg. 186.20% | Avg: $0.4 Low: -$0.02 High: $1.05 avg. 216% |
Operating Expenses
% change YoY
| $51.68M N/A | $36.49M -29.38% | $33.00M -9.55% | Avg: $52.21M Low: $12.17M High: $92.24M avg. 58.18% | Avg: $203.09M Low: $40.07M High: $463.74M avg. 288.97% | Avg: $303.68M Low: $59.91M High: $693.42M avg. 49.52% | Avg: $580.81M Low: $114.59M High: $1.32B avg. 91.25% |
FAQ
What is Lineage Cell Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 86.13% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -43.16M, average is -32.25M and high is -13.81M.
What is Lineage Cell Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 98.84% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $1.36M, average is $5.86M and high is $10.36M.
What is Lineage Cell Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 93.64% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.25, average is -$0.17 and high is $-0.08.